ScripEli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i
In VivoWhen Thijs Spoor was weighing his next career move in 2022, one option stood out despite its humble appearance. While other opportunities offered larger funding rounds and flashier platforms, a small
ScripWho: Eli Lilly/Juvena Therapeutics What: Juvena will use its AI platform JuvNET to identify stem cell-secreted protein drug candidates to help patients on obesity therapy maintain muscle mass and f
ScripIn its sixth cardiometabolic disease deal of 2025, Novo Nordisk – reportedly concerned about its standing in the obesity and diabetes space versus its nearest rival, Eli Lilly – will turn to Deep Ap